From Medscape Gastroenterology

Advances in Inflammatory Bowel Diseases (AIBD) 2019

December 12 - 14, 2019; Orlando, Florida

December 12 - 14, 2019 Orlando, Florida

AIBD 2019 Biosimilar for Crohn's Noninferior to Adalimumab A patent dispute means that the marketing of a biosimilar for patients with inflammatory bowel disease will be delayed, despite approval by the US Food and Drug Administration, investigators report.
Medscape Medical News, December 14, 2019

AIBD 2019 IBD Biomarker Unknowns Complicate Treatment
Medscape Medical News, December 17, 2019
AIBD 2019 Patients With IBD Prone to Irritable Bowel Syndrome
Medscape Medical News, December 16, 2019

AIBD 2019 Biosimilar for Crohn's Noninferior to Adalimumab
Medscape Medical News, December 14, 2019
AIBD 2019 Emerging Treatment Options for Crohn's
Medscape Medical News, December 4, 2019

Anti-TNF Agents Linked to Increased Risk for IBD A new study finds that patients with autoimmune disease treated with anti- tumor necrosis factor alpha have an increased risk of developing inflammatory bowel disease.
Medscape Medical News, Jul 15, 2019
Biologics in IBD: More Thoughtful Use Could Improve Outcomes The marketplace introduction of infliximab for the treatment of IBD did not reduce hospitalization or surgery rates in a large population of patients with Crohn disease and ulcerative colitis.
Medscape Medical News, Jun 20, 2019
Treating Depression May Mitigate IBD Risk, Study Shows Patients with depression are at increased risk of developing ulcerative colitis and Crohn's disease, but treatment with antidepressants may offer some protection.
Medscape Medical News, Oct 26, 2018

Medscape Gastroenterology© WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Related Coverage

Related Resource